Status:

UNKNOWN

French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"

Lead Sponsor:

University Hospital, Tours

Conditions:

Thrombotic Microangiopathy

Acute Kidney Injury

Eligibility:

All Genders

18+ years

Brief Summary

Thrombotic microangiopathies (TMAs) are a diverse, rare but serious group of diseases. Progress has been made regarding the epidemiology of TMA (Bayer CJASN 2019). It has been shown that secondary TMA...

Detailed Description

Thrombotic microangiopathies (TMAs) are a diverse, rare but serious group of diseases. Their epidemiology has recently been elucidated thanks to work published by our team. It has been shown that seco...

Eligibility Criteria

Inclusion

  • Adult patients 18 years of age or older
  • Who have undergone renal biopsy of the native kidney for impaired renal function between 2009 and July 2022.
  • Presence of classically defined systemic MAT (most of the following parameters: elevated LDH, decreased haptoglobin, schizocytes, thrombocytopenia and anemia) AND/OR presence of arteriolar or glomerular renal MAT as indicated by the pathologist (including endothelial turgor, mesangiolysis, double contours, presence of thrombi, fibrinoid necrosis of the arterial wall).

Exclusion

  • 1\. Kidney transplantation

Key Trial Info

Start Date :

January 1 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

1000 Patients enrolled

Trial Details

Trial ID

NCT05991245

Start Date

January 1 2023

End Date

January 1 2025

Last Update

August 14 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Nephrology, University Hospital of Tours

Tours, France, 37044